Pathogenetically-oriented therapy for novel coronavirus infection
DOI: 10.32364/2587-6821-2020-4-4-192-198
L.R. Mukhamadieva1, G.A. Mavzyutova1, E.B. Tyurina2, O.Z. Kuzovkina2
1Bashkir State Medical University, Ufa, Russian Federation
2City Clinical Hospital No. 5 of the city of Ufa, Ufa, Russian Federation
Aim: to assess clinical efficacy of azoximer bromide in the complex inpatient treatment for COVID-19.
Patients and Methods: the study included 20 patients aged 16–65 years with verified moderate novel coronavirus infection who received inpatient care. All patients were divided into two groups. Study group patients (n=10) received complex treatment that included azoximer bromide. Control group patients (n=10) received standard therapy only. The criterion of treatment efficacy was the improvement of major disease symptoms, radiographic manifestations, and pro-inflammatory laboratory tests.
Results: azoximer bromide as a component of the treatment for novel coronavirus infection provides more rapid symptom relief (i.e., cough, sputum, fever, respiratory rate) compared to the standard therapy (p<0.05). azoximer bromide also provides more rapid radiographic improvement as demonstrated by helical computed tomography, i.e., by day 14, the percentage of lung parenchyma involved was 5% in the study group and 10–12% in the control group (p<0.05). In addition, the improvement of pro-inflammatory laboratory tests (i.e., normal WBC count, decrease in ESR) was revealed as well (p<0.05).
Conclusion: azoximer bromide as a component of the complex treatment for novel coronavirus infection is associated with the clinical improvement that manifests with more rapid relief of inflammation and lung parenchyma involvement as compared with the standard therapy. N o adverse reactions were reported.
Keywords: coronavirus infection, SARS-CoV2, COVID-19, pneumonia, immune correction, pathogenetically-oriented therapy, azoximer bromide.
For citation: Mukhamadieva L.R., Mavzyutova G.A., Tyurina E.B., Kuzovkina O.Z. Pathogenetically-oriented therapy for novel coronavirus infection. Russian Medical Inquiry. 2020;4(4):–198. DOI: 10.32364/2587-6821-2020-4-4-192-198.
About the authors:
Lyaysan R. Mukhamadieva — Cand. of Sci. (Med.), assistant of the Department of Faculty Therapy, Bashkir State Medical University, 3, Lenin str., Ufa, 450000, Russian Federation; ORCID iD 0000-0002-7391-5960.
Guzel’ A. Mavzyutova — Dr. of Sci. (Med.), professor of the Department of Faculty Therapy, Bashkir State Medical University, 3, Lenin str., Ufa, 450000, Russian Federation; ORCID iD 0000-0003-2098-1435.
Elena B. Tyurina — Cand. of Sci. (Med.), therapist of the E.R., City Clinical Hospital No. 5 of the city of Ufa, 93, Parkhomenko str., Ufa, 450005, Russian Federation; ORCID iD 0000-0002-8493-3929.
Oksana Z. Kuzovkina — Cand. of Sci. (Med.), Head of Department of Palliative Care, City Clinical Hospital No. 5 of the city of Ufa, 93, Parkhomenko str., Ufa, 450005, Russian Federation; ORCID iD 0000-0003-4314-7304.
Contact information: Lyaysan R. Mukhamadieva, e-mail: leisyan.ae@mail.ru. Financial Disclosure: no authors have a financial or property interest in any material or method mentioned. There is no conflict of interests. Received 17.07.2020, revised 09.08.2020, accepted 12.08.2020.
2. Remy K.E., Brakenridge S.C., Francois B. et al. Immunotherapies for COVID-19: lessons learned from sepsis. Lancet Respir Med. 2020; S2213–2600 (20) 30217–4. DOI: 10.1016/S2213-2600 (20) 30217-4.
3. Mukhamadieva L.R., Mavzyutova G.A., Fazlyeva R.M., Bikmetova N.R. Clinical and immunological efficacy of imunofan and polyoxidonium in the complex therapy of community-acquired pneumonia Meditsynskaya immunologiya. 2009;11(1):57–62 (in Russ.).
4. Pinegin B.V., Dagil Yu.A., Vorobieva N.V., Paschenkov M.V. The effect of azoxymer bromide on the formation of extracellular neutrophil traps. RMJ. 2019;1(II):42–46 (in Russ.).
5. Karaulov A.V., Gorelov A.V. The use of azoximer bromide in the treatment of infectious and inflammatory respiratory diseases in children: a meta-analysis of controlled clinical trials. Zhurnal infektologiya. 2019;11(4):31–41 (in Russ.).
6. Zuo Y., Yalavarthi S., Shi Н. et al. Neutrophil extracellular traps in COVID-19. JCI Insight. 2020;5(11): e138999. DOI: 10.1172/jci.insight.138999.
7. Pružinec P., Chirun N., Sveikata A. The safety profile of Polyoxidonium in daily practice: results from postauthorization safety study in Slovakia. Immunotherapy. 2018;10(2):131–137. DOI: 10.2217/imt-2017-0116.
8. Vyšetrovací algoritmus a medikamentózna liečba pacientov nad 65 rokov, pacientov so závažným priebehom a polymorbídnych pacientovpočas hospitalizácie na infekčnom oddelení. (Electronic resource). URL: https://standardnepostupy.sk/_files/200000421–45c4245c44/COVID-19%20hospitalizovan%C3%AD%20pacientiv...% 20verzia% 202.0.pdf. Access date: 13.07.2020.
9. Mavzyutova G.A., Mukhamadieva L.R., Fazlyeva R.M. et al. Rational immunocorrection in the complex therapy of community-acquired pneumonia. Meditsinskiy sovet. 2015;16:68–73 (in Russ.).
10. Averkiev V.L., Tarasenko V.S., Latysheva T.V. et al. Correction of immunological disorders in patients with pancreatic necrosis Immunologiya. 2002;6:359–363 (in Russ.).
11. Mavzyutova G.A., Mukhamadieva L.R., Avzaletdinov A.M. et al. Immunological disorders in acute post-pneumonic abscesses and their correction. Meditsinskiy vestnik Bashkortostanf. 2010;5(2):19–24 (in Russ.).
12. Gavrilyuk V.P., Konoplya A.I. The effect of immunomodulatory drugs on the course of appendicular peritonitis in children. Detskaya khirurgiya. 2012;4:36–38 (in Russ.).
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Распечатать